NCT03805698 is a NA clinical trial of Platelet-rich Plasma (PRP) in Arthroscopic Surgery, sponsored by Cedars-Sinai Medical Center.

Who is sponsoring NCT03805698?

NCT03805698 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT03805698?

Interventions in NCT03805698: Platelet-rich Plasma (PRP), Standard Arthroscopic Debridement.

What condition does NCT03805698 study?

NCT03805698 studies Arthroscopic Surgery, Triangular Fibrocartilage Complex Injury.

Is NCT03805698 still recruiting?

NCT03805698 is currently terminated. Last updated 6 October 2022.

Are results published for NCT03805698?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-10-06 · How we verify

NCT03805698

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears

Terminated NA Results posted Last updated 6 October 2022

What this trial tests

NA trial testing Platelet-rich Plasma (PRP) in Arthroscopic Surgery in 10 participants. Terminated before completion.

Timeline

3 January 2019

Primary endpoint
6 February 2021

6 February 2021

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	3 January 2019
Primary completion	6 February 2021
Estimated completion	6 February 2021
Sites	1 location across United States

Drugs / interventions tested

Platelet-rich Plasma (PRP)
Standard Arthroscopic Debridement

Conditions studied

Arthroscopic Surgery — all drugs for Arthroscopic Surgery →
Triangular Fibrocartilage Complex Injury — all drugs for Triangular Fibrocartilage Complex Injury →

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Arthroscopic Surgery or Triangular Fibrocartilage Complex Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to compare outcomes and functionality measures of subjects treated with platelet rich plasma (PRP) after arthroscopic debridement of triangular fibrocartilage complex (TFCC) tears to subjects treated with arthroscopic debridement alone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Platelet-rich Plasma (PRP)

Trials testing the same drug.

NCT06283745 — Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia · NA · recruiting

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03805698 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 6 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03805698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing